A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis | Zendy

David H. Miller | Zendy; Omar Khan | Zendy; William Sheremata | Zendy; Lance D. Blumhardt | Zendy; George P. Rice | Zendy; Michele Libonati | Zendy; A. Willmer–Hulme | Zendy; Catherine M. Dalton | Zendy; Katherine Miszkiel | Zendy; Paul O’Connor | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Author(s) -

David H. Miller,

Omar Khan,

William Sheremata,

Lance D. Blumhardt,

George P. Rice,

Michele Libonati,

A. Willmer–Hulme,

Catherine M. Dalton,

Katherine Miszkiel,

Paul O’Connor

Publication year - 2003

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa020696

Subject(s) - natalizumab , medicine , multiple sclerosis , kilogram , placebo , gastroenterology , randomized controlled trial , surgery , urology , immunology , pathology , body weight , alternative medicine

In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving activated lymphocytes and monocytes. The glycoprotein alpha4 integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Natalizumab is an alpha4 integrin antagonist that reduced the development of brain lesions in experimental models and in a preliminary study of patients with multiple sclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research